Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

788
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
788

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Quantitative assessment of additive effects of mirabegron and solifenacin in overactive bladder: re-analysis of SYNERGY study.

Urology·2026
Same author

Postoperative Management After Pathological Complete Response to Neoadjuvant Therapy for Muscle-Invasive Bladder Cancer: An Exploratory Reconstructed Individual Patient Data Analysis.

Clinical genitourinary cancer·2026
Same author

Bayesian Methods for Subgroup Efficacy and Safety: Application to Japanese Patients in JAVELIN Renal 101.

JCO clinical cancer informatics·2026
Same author

Bayesian Analysis to Refine East Asian Subgroup Estimates in the CLEAR Trial (Lenvatinib Plus Pembrolizumab <i>vs</i>. Sunitinib) for Advanced Renal Cell Carcinoma.

Anticancer research·2026
Same author

Comparison of the effects of low-irradiance and high-irradiance phototherapy on non-hemolytic neonatal jaundice.

Scientific reports·2026
Same author

Auditory Involvement in Inflammatory Bowel Disease: Clinical Predictors and Prognostic Implications.

Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology·2026

Related Experiment Video

Updated: Feb 19, 2026

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

17.2K

Prognostic parameter for high risk prostate cancer patients at initial presentation.

Masashi Kato1, Kyosuke Kimura2, Akihiro Hirakawa3

  • 1Department of Urology, Nagoya University Graduate School of Medicine, Nagoya, Japan.

The Prostate
|November 3, 2017
PubMed
Summary

Intraductal carcinoma of the prostate (IDC-P) in needle biopsies indicates worse outcomes for high-risk prostate cancer patients. Early detection and tailored therapies are crucial for improving progression-free survival (PFS) and cancer-specific survival (CSS).

Keywords:
IDC-P (intraductal carcinoma of the prostate)biopsyhigh risk prostate cancerradical prostatectomy

More Related Videos

Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

9.5K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.9K

Related Experiment Videos

Last Updated: Feb 19, 2026

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

17.2K
Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

9.5K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.9K

Area of Science:

  • Urology
  • Oncology
  • Pathology

Background:

  • High-risk prostate cancer is defined by Gleason score (GS), PSA level, and cT stage.
  • Disease heterogeneity necessitates novel prognostic markers beyond traditional indicators.
  • Intraductal carcinoma of the prostate (IDC-P) presence in needle biopsy requires evaluation as a prognostic parameter.

Purpose of the Study:

  • To assess if IDC-P in needle biopsy predicts progression-free survival (PFS) and cancer-specific survival (CSS).
  • To evaluate IDC-P as a prognostic factor in patients with high-risk prostate cancer undergoing radical prostatectomy.

Main Methods:

  • Retrospective analysis of 204 high-risk prostate cancer patients treated with radical prostatectomy (1991-2005).
  • Data collected included PSA, biopsy GS, cT stage, Gleason pattern 5, IDC-P presence, and core involvement percentage.
  • Statistical analysis using Fine and Gray's model for PFS and CSS, and multivariate Cox regression for overall survival (OS).

Main Results:

  • IDC-P was detected in 36% of needle biopsy samples.
  • Patients with IDC-P had significantly lower 5-, 10-, and 15-year CSS rates compared to IDC-P negative cases (P=0.0001).
  • IDC-P was a significant predictor for PFS (P=0.013), CSS (P=0.027), and OS (HR 1.95, P=0.04) in multivariate analyses.

Conclusions:

  • IDC-P presence in needle biopsy is a significant adverse prognostic factor for PFS, CSS, and OS in high-risk prostate cancer.
  • Findings suggest the need for multimodal therapy (pre- and/or post-surgical) when IDC-P is identified.
  • IDC-P serves as a critical marker for stratifying risk and guiding treatment decisions in high-risk prostate cancer.